Floatz logo

Panobinostat

Head and Neck Cancer

University of PittsburghSmall moleculePhase 1Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
73/ 100

Competitive context

114 Active assets in the Head and Neck Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
ImmunityBio, Inc.
Phase 3BB
Carboplatin
Rapa Therapeutics LLC
Phase 3BB
Pembrolizumab
Thomas Jefferson University
Phase 3BB
Cetuximab
Pfizer
Phase 3BB
FILGRASTIM
University of Colorado, Denver
Phase 2BB

View all 50 →

Same molecule, other indications

Panobinostat is also rated in:

Hodgkins lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
Non-Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →